201 related articles for article (PubMed ID: 36290035)
1. Off-Label Use of Dalbavancin for Sequential Treatment of Spondylodiscitis by Methicillin-Resistant
Mazzitelli M; Gatti M; Scaglione V; Mengato D; Trevenzoli M; Sattin A; Pea F; Cattelan AM
Antibiotics (Basel); 2022 Oct; 11(10):. PubMed ID: 36290035
[TBL] [Abstract][Full Text] [Related]
2. Multiple Weekly Dalbavancin Dosing for the Treatment of Native Vertebral Osteomyelitis Caused by Methicillin-Resistant Staphylococcus Aureus: A Case Report.
Almangour TA; Fletcher V; Alessa M; Alhifany AA; Tabb D
Am J Case Rep; 2017 Dec; 18():1315-1319. PubMed ID: 29222405
[TBL] [Abstract][Full Text] [Related]
3. French national cohort of first use of dalbavancin: A high proportion of off-label use.
Dinh A; Duran C; Pavese P; Khatchatourian L; Monnin B; Bleibtreu A; Denis E; Etienne C; Rouanes N; Mahieu R; Bouchand F; Davido B; Lotte R; Cabaret P; Camou F; Chavanet P; Assi A; Limonta S; Lechiche C; Riou R; Courjon J; Illes G; Lacassin-Beller F; Senneville E;
Int J Antimicrob Agents; 2019 Nov; 54(5):668-672. PubMed ID: 31400471
[TBL] [Abstract][Full Text] [Related]
4. Clinical failure of dalbavancin for MRSA bacteremia in patient with severe obesity and history of IVDU.
Ritchie H; Aggarwal A; Schimmel J; Lorenzo MP
J Infect Chemother; 2022 Mar; 28(3):465-468. PubMed ID: 35016828
[TBL] [Abstract][Full Text] [Related]
5. Dalbavancin treatment for prosthetic joint infections in real-life: a national cohort study and literature review.
Matt M; Duran C; Courjon J; Lotte R; Moing VL; Monnin B; Pavese P; Chavanet P; Khatchatourian L; Tattevin P; Cattoir V; Lechiche C; Illes G; Lacassin-Beller F; Senneville E; Dinh A;
J Glob Antimicrob Resist; 2021 Jun; 25():341-345. PubMed ID: 33962065
[TBL] [Abstract][Full Text] [Related]
6. Real-World Data Regarding Dalbavancin Use before and during the COVID-19 Pandemic-A Single-Center Retrospective Study.
Ioannou P; Wolff N; Mathioudaki A; Spanias C; Spernovasilis N; Kofteridis DP
Antibiotics (Basel); 2023 Jul; 12(7):. PubMed ID: 37508301
[TBL] [Abstract][Full Text] [Related]
7. Evaluating the Use of Dalbavancin for Off-Label Indications.
Taylor K; Williamson J; Luther V; Stone T; Johnson J; Gruss Z; Russ-Friedman C; Ohl C; Beardsley J
Infect Dis Rep; 2022 Apr; 14(2):266-272. PubMed ID: 35447884
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Suppressive Therapeutic-Drug-Monitoring-Guided Dalbavancin Therapy for Cardiovascular Prosthetic Infections.
Gallerani A; Gatti M; Bedini A; Casolari S; Orlando G; Puzzolante C; Franceschini E; Menozzi M; Santoro A; Barp N; Volpi S; Soffritti A; Pea F; Mussini C; Meschiari M
Antibiotics (Basel); 2023 Nov; 12(11):. PubMed ID: 37998841
[TBL] [Abstract][Full Text] [Related]
9. Dalbavancin treatment for spondylodiscitis: multi-center clinical experience and literature review.
Ramadan MS; Gallo R; Lugarà M; Gambardella M; Oliva G; Bertolino L; Andini R; Coppola N; Zampino R; Durante-Mangoni E
J Chemother; 2022 Oct; 34(6):360-366. PubMed ID: 34923922
[TBL] [Abstract][Full Text] [Related]
10. Dalbavancin Use for the Treatment of Methicillin-resistant
Barber KE; Tirmizi A; Finley R; Stover KR
J Pharmacol Pharmacother; 2017; 8(2):77-79. PubMed ID: 28706403
[TBL] [Abstract][Full Text] [Related]
11. Acute Bacterial Skin and Skin-Structure Infections, efficacy of Dalbavancin: a systematic review and meta-analysis.
Monteagudo-Martínez N; Solís-García Del Pozo J; Nava E; Ikuta I; Galindo M; Jordán J
Expert Rev Anti Infect Ther; 2022 Nov; 20(11):1477-1489. PubMed ID: 32981375
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of dalbavancin against methicillin-resistant Staphylococcus aureus in the rat granuloma pouch infection model.
Jabés D; Candiani G; Romanó G; Brunati C; Riva S; Cavaleri M
Antimicrob Agents Chemother; 2004 Apr; 48(4):1118-23. PubMed ID: 15047510
[TBL] [Abstract][Full Text] [Related]
13. Dalbavancin exposure in vitro selects for dalbavancin-non-susceptible and vancomycin-intermediate strains of methicillin-resistant Staphylococcus aureus.
Werth BJ; Ashford NK; Penewit K; Waalkes A; Holmes EA; Ross DH; Shen T; Hines KM; Salipante SJ; Xu L
Clin Microbiol Infect; 2021 Jun; 27(6):910.e1-910.e8. PubMed ID: 32866650
[TBL] [Abstract][Full Text] [Related]
14. Dalbavancin for treatment of implant-related methicillin-resistant Staphylococcus aureus osteomyelitis in an experimental rat model.
Kussmann M; Obermueller M; Berndl F; Reischer V; Veletzky L; Burgmann H; Poeppl W
Sci Rep; 2018 Jun; 8(1):9661. PubMed ID: 29941909
[TBL] [Abstract][Full Text] [Related]
15. Clinical experience with dalbavancin for the treatment of deep sternal wound infection.
Bartoletti M; Mikus E; Pascale R; Giannella M; Tedeschi S; Calvi S; Tenti E; Tumietto F; Viale P
J Glob Antimicrob Resist; 2019 Sep; 18():195-198. PubMed ID: 30926464
[TBL] [Abstract][Full Text] [Related]
16. Dalbavancin Alone and in Combination with Ceftaroline against Four Different Phenotypes of
Kebriaei R; Rice SA; Stamper KC; Rybak MJ
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670436
[TBL] [Abstract][Full Text] [Related]
17. Update on activity of dalbavancin and comparators against clinical isolates of Gram-positive pathogens from Europe and Russia (2017-2018), and on clonal distribution of MRSA.
Riccobono E; Giani T; Baldi G; Arcangeli S; Antonelli A; Tellone V; Del Vecchio A; De Joannon AC; Rossolini GM
Int J Antimicrob Agents; 2022 Feb; 59(2):106503. PubMed ID: 34929289
[TBL] [Abstract][Full Text] [Related]
18. Real world utilization of Dalbavancin at a rural community emergency department.
Dolan A; Kuge E; Bremmer E; Dietrich T; Santarelli A; Ashurst J
Am J Emerg Med; 2022 Apr; 54():253-256. PubMed ID: 35190304
[TBL] [Abstract][Full Text] [Related]
19. In Vitro Activity of Dalbavancin against Refractory Multidrug-Resistant (MDR)
Bongiorno D; Lazzaro LM; Stefani S; Campanile F
Antibiotics (Basel); 2020 Dec; 9(12):. PubMed ID: 33287376
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens.
Raad I; Darouiche R; Vazquez J; Lentnek A; Hachem R; Hanna H; Goldstein B; Henkel T; Seltzer E
Clin Infect Dis; 2005 Feb; 40(3):374-80. PubMed ID: 15668859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
